Super-enhancers: novel target for pancreatic ductal adenocarcinoma
(Rapamycin Press) Among many pathways of cancer progression that PDAC relies on, anomalous activation of the sonic hedgehog pathway has shown in a variety of human cancers, including, basal cell carcinoma, malignant gliomas, medulloblastoma, leukemias, and cancers of the breast, lung, pancreas, and prostate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 26, 2019 Category: Cancer & Oncology Source Type: news

FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
PRINCETON, N.J., Feb. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric ... Biopharmaceuticals, Oncology, FDA Taiho Oncology, LONSURF, trifluridine, tipiracil, Gastric cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 25, 2019 Category: Pharmaceuticals Source Type: news

Mother was forced to have her EYE removed after a rare cancer spread across her face  
Toni Crews, 29, of Deal, Kent, began battling blurred vision and headaches in July 2016. She was diagnosed with adenocarcinoma - a type of cancer in the gland of her right eye. (Source: the Mail online | Health)
Source: the Mail online | Health - February 25, 2019 Category: Consumer Health News Source Type: news

FDA Approves Lonsurf (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
PRINCETON, N.J., February 25, 2019– Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved Lonsurf as a treatment for adult patients with metastatic gastric or gastroesophageal junction... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 25, 2019 Category: Drugs & Pharmacology Source Type: news

Results of early endoscopic exam critical for assessment of Barrett's patients
(American Society for Gastrointestinal Endoscopy) A new study indicates that both high-grade abnormal cellular changes (dysplasia) and esophageal adenocarcinoma (a form of cancer) have increased in the last 25 years among people with a digestive condition known as Barrett's esophagus. The study report, Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades, is published in the February issue of GIE: Gastrointestinal Endoscopy, the peer-reviewed journal of the American Society for Gastrointestinal Endoscopy (ASGE). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 14, 2019 Category: International Medicine & Public Health Source Type: news

Mapping oesophageal cancer genes leads to new drug targets
(Cancer Research UK) Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail -- unveiling that more than half could be targeted by drugs currently in trials for other cancer types. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 4, 2019 Category: Biology Source Type: news

Reading the signs: Semaphorin linked to lung cancer treatment resistance
(Osaka University) Osaka University researchers showed that high levels of the protein Semaphorin 7a are associated with resistance to treatment with EGFR-TKIs in lung adenocarcinoma cells with EGFR mutation. The findings revealed the involvement of mTOR signaling in this effect, as well as the importance of the inhibition of apoptosis. The findings suggest that focusing on Semaphorin 7a could be advantageous for predicting the prognosis of lung cancer patients and potentially for treating them. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 10, 2019 Category: Cancer & Oncology Source Type: news

Adjuvant Therapy Questioned for Patients With Small Pancreatic Tumors
Investigators evaluated whether patients with pancreatic ductal adenocarcinoma benefit from adjuvant therapy after surgery if the tumor is smaller than 1 cm. (Source: CancerNetwork)
Source: CancerNetwork - January 4, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Pembrolizumab Shows Modest Activity in Advanced Esophageal Cancer Pembrolizumab Shows Modest Activity in Advanced Esophageal Cancer
Pembrolizumab benefits a minority of heavily pretreated patients with advanced metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, according to an open-label phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Bladder Cancer | Medscape Bladder Cancer | Medscape
Bladder cancer is the second most common urologic malignancy. Transitional cell carcinoma accounts for more than 90% of cases; other types include squamous cell carcinoma and adenocarcinoma. In stage 1 disease, when the tumors are superficial, bladder cancer is treatable with transurethral resection and intravesical therapy. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news

VARGADO data
Vargatef ® plus docetaxel could be an option after failure of immunotherapy in lung cancerResults from a real-world study1  support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2018 Category: Research Source Type: news

Intraoperative Consultation on Surgical Margins 98% Accurate in Gastric Cancer Intraoperative Consultation on Surgical Margins 98% Accurate in Gastric Cancer
The false-negative rate of intraoperative consultation (IOC) on surgical margins during resection of gastric and gastroesophageal adenocarcinoma is less than 2% overall, according to a retrospective study at a specialty center.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 6, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Pancreatic cancer genetic marker may predict outcomes with radiation therapy
(Thomas Jefferson University) scientists find that a gene involved in the immune system called IDO2 plays a significant role in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The discovery may help physicians provide better treatment options for patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

Short-term ADT with RT improves survival over RT alone up to 10 years
(NRG Oncology) The long-term follow up of the NRG Oncology trial RTOG 9408, studying the addition of short-term androgen-deprivation therapy (ADT) to radiotherapy (RT) for men with early, localized prostate adenocarcinoma, indicated that RT combined with ADT is superior to RT alone for overall survival (OS) up to 10.4 years following treatment. However, when researchers assessed these results up to 18 years, the benefits of adding ADT to RT dissipated. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

Increased survival in patients with metastatic NSCLC receiving treatment in academic centers
(International Association for the Study of Lung Cancer) Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs). An overall histology-dependent survival was also noted in patients with adenocarcinoma verses squamous cell carcinoma and varied by treatment facility. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2018 Category: Cancer & Oncology Source Type: news